€26m financing for ISA PharmaceuticalsDutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers. more ➔
Unilever licences Arzeda Inc.s enzyme te...As part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon. more ➔
Novo Nordisk invests in amyloidosis pipeli...Danish Novo Nordisk is moving out of the diabetes space and taking over Prothenas ATTR amyloidosis programme – including a Phase II-ready immunotherapy. more ➔
Sanofi invests heavily in multiple myeloma... Sanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment. more ➔
Bio-Me raises NOK10mOslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round. more ➔
NFL Biosciences goes public, raises €5mFrench biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris. more ➔
Promethera bags €20m for liver failure t...With a €20m financing round under its belt, Promethera Therapeutics is poised to start its Phase IIb study for its stem cell therapy treating liver failure. more ➔
Novalis Biotech closes biotech fund at €...Early-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at €25m to drive growth of translational medicine start-ups. more ➔
Cellink AB to take-over Discover Echo IncSwedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares. more ➔
Rheincell set to be acquired by CatalentMajor CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies. more ➔
